Inability to produce a model of dialysis encephalopathy in the rat by aluminum administration.
We attempted to produce a rat model of brain aluminum toxicity in order to explore whether or not aluminum accumulation produces the neurochemical changes observed in brains of patients who die with dialysis encephalopathy. Daily subcutaneous injection of Al(OH)3 caused marked elevation of serum aluminum concentrations, but did not increase brain aluminum contents, either in rats with normal renal function, or in rats with unilateral or 5/6 nephrectomies. LiCl pretreatment, which has been reported to cause irreversible renal failure, did not impair renal function nor aid in achieving elevated brain aluminum contents. No reductions in brain contents of gamma-aminobutyric acid (GABA) or in glutamic acid decarboxylase (GAD, E.C.4.1.1.15) and choline acetyltransferase (ChAT, E.C.2.3.1.6) activities were observed in aluminum-treated rats. We conclude that the rat is not a suitable laboratory animal to explore the role of aluminum toxicity in causing the GABA and ChAT deficits present in brains of hemodialyzed human patients.
D000536:Aluminum Hydroxide / Q000633:toxicity*; D000818:Animals; D001923:Brain Chemistry; D001927:Brain Diseases / Q000139:chemically induced*; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D005968:Glutamate Decarboxylase / Q000378:metabolism; D007674:Kidney Diseases / Q000139:chemically induced; D008094:Lithium / Q000633:toxicity; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D006435:Renal Dialysis / Q000009:adverse effects*; D005680:gamma-Aminobutyric Acid / Q000032:analysis
D005680:gamma-Aminobutyric Acid; D000536:Aluminum Hydroxide; D008094:Lithium; D002795:Choline O-Acetyltransferase; D005968:Glutamate Decarboxylase